CINECA IRIS Institutional Research Information System

CONVERTINO, IRMA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.827
AS - Asia 2.905
EU - Europa 2.117
SA - Sud America 512
AF - Africa 263
OC - Oceania 35
Continente sconosciuto - Info sul continente non disponibili 9
Totale 10.668
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.706
SG - Singapore 928
IT - Italia 639
CN - Cina 621
HK - Hong Kong 412
BR - Brasile 383
SE - Svezia 318
VN - Vietnam 301
GB - Regno Unito 230
DE - Germania 209
IN - India 173
FR - Francia 154
BG - Bulgaria 124
FI - Finlandia 113
JP - Giappone 106
CI - Costa d'Avorio 90
TR - Turchia 77
RU - Federazione Russa 66
CA - Canada 59
NL - Olanda 58
SN - Senegal 57
ID - Indonesia 42
AT - Austria 40
BD - Bangladesh 35
PL - Polonia 35
AU - Australia 34
IQ - Iraq 34
NG - Nigeria 34
AR - Argentina 32
MX - Messico 32
ES - Italia 24
KR - Corea 23
CO - Colombia 22
SA - Arabia Saudita 21
CL - Cile 19
EC - Ecuador 19
ZA - Sudafrica 19
UZ - Uzbekistan 18
VE - Venezuela 15
PT - Portogallo 14
EG - Egitto 13
PK - Pakistan 13
UA - Ucraina 13
IR - Iran 12
MA - Marocco 12
MY - Malesia 11
CZ - Repubblica Ceca 10
IE - Irlanda 10
LT - Lituania 10
JO - Giordania 9
KE - Kenya 9
PE - Perù 9
AE - Emirati Arabi Uniti 7
BE - Belgio 7
CH - Svizzera 7
PY - Paraguay 7
CR - Costa Rica 6
IL - Israele 6
JM - Giamaica 6
PH - Filippine 6
AZ - Azerbaigian 5
GR - Grecia 5
KZ - Kazakistan 5
TH - Thailandia 5
XK - ???statistics.table.value.countryCode.XK??? 5
DZ - Algeria 4
ET - Etiopia 4
EU - Europa 4
GH - Ghana 4
LV - Lettonia 4
NP - Nepal 4
PS - Palestinian Territory 4
RO - Romania 4
TN - Tunisia 4
TT - Trinidad e Tobago 4
TW - Taiwan 4
AL - Albania 3
BW - Botswana 3
DK - Danimarca 3
DO - Repubblica Dominicana 3
HR - Croazia 3
KG - Kirghizistan 3
LB - Libano 3
NI - Nicaragua 3
OM - Oman 3
RS - Serbia 3
AO - Angola 2
BO - Bolivia 2
GT - Guatemala 2
LY - Libia 2
MK - Macedonia 2
QA - Qatar 2
SK - Slovacchia (Repubblica Slovacca) 2
TJ - Tagikistan 2
UY - Uruguay 2
AM - Armenia 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BH - Bahrain 1
BJ - Benin 1
Totale 10.641
Salva come PNG Salva come JPEG
Città #
Ashburn 624
Singapore 538
Hong Kong 406
San Jose 376
Santa Clara 362
Dallas 250
Chandler 214
Shanghai 212
Fairfield 185
Sofia 123
Florence 116
New York 116
Boardman 111
Beijing 101
Woodbridge 100
Houston 98
Los Angeles 98
London 94
Abidjan 90
Ho Chi Minh City 90
Ann Arbor 87
Tokyo 85
Munich 75
Hanoi 72
Wilmington 72
Milan 71
Princeton 71
Helsinki 65
Lauterbourg 60
Dakar 57
Seattle 57
Istanbul 56
Cambridge 55
Lawrence 53
Pisa 52
Serra 49
Medford 45
Rome 37
Council Bluffs 36
Frankfurt am Main 33
Lagos 33
Turku 33
Mumbai 29
Kent 28
Redwood City 28
Rio de Janeiro 27
Buffalo 26
Redondo Beach 26
Dong Ket 25
São Paulo 25
Bremen 24
Chicago 23
Vienna 23
Warsaw 23
Hyderabad 22
San Francisco 22
Massa 19
Washington 19
Hefei 18
Jakarta 18
Amsterdam 16
Brooklyn 16
Denver 16
Ottawa 16
San Diego 16
Tashkent 16
Da Nang 15
Atlanta 14
Chennai 14
Fuzhou 14
Mexico City 14
Orem 14
Phoenix 14
Santiago 14
Johannesburg 13
Ogden 13
Baghdad 12
Nuremberg 12
Düsseldorf 11
Modugno 11
Montreal 11
Norwalk 11
Curitiba 10
Haiphong 10
Manchester 10
Paris 10
Toronto 10
Bengaluru 9
Livorno 9
Melbourne 9
Mountain View 9
Nairobi 9
Riyadh 9
Sydney 9
Amman 8
Belo Horizonte 8
Birmingham 8
Cairo 8
Cascina 8
Dublin 8
Totale 6.447
Salva come PNG Salva come JPEG
Nome #
Raynaud’s Phenomenon Associated with Calcitonin Gene-Related Peptide (CGRP) Antagonists: a Disproportionality Analysis on VigiBase 839
The Anti-TNF Drugs and the Risk of Lymphoma, Skin Cancer and Melanoma: A Signal Detection Analysis 203
Neonatal Adaptation Issues After Maternal Exposure to Prescription Drugs: Withdrawal Syndromes and Residual Pharmacological Effects 202
Expected and actual adverse drug-drug interactions in elderly patients accessing the emergency department: data from the ANCESTRAL-ED study 200
Trajectories of oral budesonide use in Crohn's disease cohort of Tuscan patients (Italy) 198
Direct health care costs among patients with rheumatoid arthritis before and after the initiation of treatment with JAKi in Tuscany: The LEONARDO study 178
Longitudinal adherence trajectories to biologic disease modifying anti-rheumatic drugs in Tuscany, Italy 175
Diagnostic delay, effectiveness and safety outcomes in a real-world cohort of patients with Crohn's disease: Data from administrative databases in Tuscany, Italy 174
Allopurinol adherence among patients with gout: an Italian general practice database study 172
Diabetes drugs and the incidence of solid cancers: a survey of the current evidence 170
Adherence to mesalazine and identification of patients with ulcerative colitis in healthcare administrative databases of Tuscany (Italy) 165
Utilisation patterns and clinical impact of the introduction of infliximab-biosimilar in Tuscany, Italy: real world evidence following the recommendation of switching for non-medical reasons 159
Validation test for algorithms to identify rheumatoid arthritis patients in the Tuscan healthcare administrative databases 159
Antibiotic Drugs and Unresolved Sensory Side Effects: Analysis of Eudravigilance Database of Suspected Adverse Drug Reaction Reports 158
Potential Direct Costs of Adverse Drug Events and Possible Cost Savings Achievable by their Prevention in Tuscany, Italy: A Model-Based Analysis 155
Olfactory and gustatory impairments in COVID-19 patients: Role in early diagnosis and interferences by concomitant drugs 150
The usefulness of listening social media for pharmacovigilance purposes: a systematic review 149
Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline 147
Fatal Fat Overload Syndrome Following Intravenous Lipid Emulsion Administration as Antidote in Suspected Anesthetic Intoxication: A Fatal Medication Error. 146
Muscular Adverse Drug Reactions Associated with Proton Pump Inhibitors: A Disproportionality Analysis Using the Italian National Network of Pharmacovigilance Database 145
Assessing disease activity of rheumatoid arthritis patients and drug-utilization patterns of biologic disease-modifying antirheumatic drugs in the Tuscany region, Italy 142
Analysis of fatal adverse drug events recorded in several Italian emergency departments (the MEREAFaPS study) 141
Time to biologic treatment and to total colectomy associated with diagnostic delay in ulcerative colitis: Analysis of an Italian regional administrative healthcare database 138
QT Interval Prolongation and Hydroxyzine: A Retrospective Cohort Analysis on Hospitalized Elderly Patients 137
Is There a Risk of Lymphoma Associated With Anti-tumor Necrosis Factor Drugs in Patients With Inflammatory Bowel Disease? A Systematic Review of Observational Studies 137
Validation of algorithms for selecting rheumatoid arthritis patients in the Tuscan healthcare administrative databases 135
Potential and Actual Drug-Drug Interactions in Elderly Patients Admitted to an Emergency Department: Data from the ANCESTRAL-ED Study 134
Recommendations by the Tuscan Health Authority to Use Infliximab-Biosimilar in the Clinical Practice: Safety Impact 134
Listening Social Media for Pharmacovigilance Objectives: Which Usefulness? 134
Trajectories of use of biologic disease modifying antirheumatic drugs in rheumatoid arthritis: A cohort study of Tuscan patients, Italy 133
Anticoagulant Therapy and Risk of Bleeding in Patients with Atrial Fibrillation of Four Italian Regions: The TYRION Study 133
Bleeding Related to Oral Anticoagulant Drugs as Cause of Emergency Department Admission: Analysis of Data from the Tuscan MEREAFaPS Network 132
Utilization patterns and healthcare accesses of JAKi used in rheumatoid arthritis patients in Tuscany: The LEONARDO study 131
Trajectories of Adherence to Biologic Disease-Modifying Anti-Rheumatic Drugs in Tuscan Administrative Databases: The Pathfinder Study 130
Erratum to: Deliberate Self-Poisoning: Real-Time Characterization of Suicidal Habits and Toxidromes in the Food and Drug Administration Adverse Event Reporting System (Drug Safety, (2023), 46, 3, (283-295), 10.1007/s40264-022-01269-x) 128
Adverse drug reactions in oncoLogy: intEnsive monitoring program on biotechnological anD taRget therapies in Oncologic patientS-ALEXANDROS observational study 128
An overview of the preclinical discovery and development of bamlanivimab for the treatment of novel coronavirus infection (COVID-19): reasons for limited clinical use and lessons for the future 128
Disproportionality Analysis of ‘‘Early-Onset’’ Tardive Dyskinesia Stratified by Time to Onset Using FAERS Database. 127
The Economic Impact of the Introduction of Infliximab-Biosimilar: Preliminary Results from a Study on Rheumatologic Patients in Tuscany, Italy 127
IntenSive Monitoring Program of TeratOgen and Non-Teratogen Risk of Drugs During Pregnancy: the STORK Project 127
THE ECONOMIC IMPACT OF THE INTRODUCTION OF INFLIXIMAB-BIOSIMILAR: AN EMPIRICAL ANALYSIS USING THE TUSCANY HEALTHCARE ADMINISTRATIVE DATABASES 127
Unresolved gustatory, olfactory and auditory adverse drug reactions to antibiotic drugs: a survey of spontaneous reporting to Eudravigilance 125
Exploring the relationship between utilization patterns of biologic disease-modifying anti-rheumatic drugs and disease activity in rheumatoid arthritis patients 122
A clinician network for sharing patients experiences in pharmacovigilance: the PHARMACOWIKILANCE project 122
Estimation of Theoretical Cost Preventability Achievable with an Effective Pharmacovigilance Activity in a Pharmacovigilance Regional Centre in Italy 120
Characterization of the Risk of Bleeding with Novel Oral Anticoagulants and Warfarin: A Pilot Case-Control Study 119
Evaluation of drug-utilization and healthcare facilities use in patients with ulcerative colitis and treated with biologic therapy using data of an Italian healthcare administrative database: Results from michelangelo study 118
Safety Profile of Certolizumab Pegol in Patients with Immune-Mediated Inflammatory Diseases: A Systematic Review and Meta-Analysis 116
Anti-tumor Necrosis Factor Drugs and Risk of Lymphoma in Patients with Inflammatory Bowel Disease 113
Anticoagulant Therapy in Patients with Atrial Fibrillation and Risk of Bleeding: Interim Analysis: Tyrion Study 111
Risk of hospitalisation associated with benzodiazepines and z-drugs in Italy: a nationwide multicentre study in emergency departments 111
Exploring pharmacological approaches for managing cytokine storm associated with pneumonia and acute respiratory distress syndrome in COVID-19 patients 111
Update of Certolizumab Pegol Safety Profile: A Systematic Review and Meta-Analysis 111
Analysis of the Drug Related Emergency Department Admissions in Tuscany: The FARO Project 110
Discontinuation rate to biologic and targeted synthetic DMARDs in rheumatoid arthritis patients: Systematic review and meta-analysis 110
Large-Scale Postmarketing Surveillance of Biological Drugs for Immune-Mediated Inflammatory Diseases Through an Italian Distributed Multi-Database Healthcare Network: The VALORE Project 109
A Model-Based Analysis on Direct Costs of Adverse Drug Events and Related Cost-Savings Achievable by their Prevention in Tuscany, Italy 108
The Impact of the COVID-19 “Infodemic” on Drug-Utilization Behaviors: Implications for Pharmacovigilance 107
A regulatory overview of biosimilars across selected countries 102
Italian Emergency Department Visits and Hospitalizations for Outpatients’ Adverse Drug Events: 12-Year Active Pharmacovigilance Surveillance (The MEREAFaPS Study) 101
Switching from infliximab-originator to infliximab-biosimilar in rheumatologic patients: The clinical impact in Tuscan Region, Italy 100
Drug-Utilization, Healthcare Facilities Accesses and Costs of the First Generation of JAK Inhibitors in Rheumatoid Arthritis 96
Challenges of Pharmacovigilance in the Neonate 96
Muscular adverse drug reactions associated with proton pump inhibitors: a disproportionality analysis using the Italian National Network of Pharmacovigilance database 96
Potential missed diagnoses of Crohn's disease in tertiary care: impact on drug utilization and healthcare facilities use 94
Supporting the Spontaneous Reporting by Health Care Professionals of the University Hospital of Pisa, Italy: a Pilot Project from the Unit of Adverse Drug Reactions Monitoring 94
Severe Cardiac Events Following Treatment with Trastuzumab in Women with Breast Cancer: A Meta-Analysis of Clinical Trials and Cohort Studies 92
Oral Presentation: Signal of Hypertension Associated with COVID-19 Vaccination: VigiBase (R) Data and Evidence from Real World 89
Communicating Drug Safety 89
Fat overload syndrome following intravenous lipid emulsion administration as antidote in suspected anesthetic intoxication: insights from a clinical and forensic case experience 87
Assessment of Healthcare Facilities Associated with JAKi Drugs Used in Rheumatoid Arthritis Patients in Tuscany, Italy: The LEONARDO 86
Biosimilars approvals by thirteen regulatory authorities: A cross-national comparison 81
Tixagevimab + cilgavimab against SARS-CoV-2: the preclinical and clinical development and real-world evidence 80
Oral Presentation: Accesses to Emergency Department and Hospitalizations in New Users of Biologic Therapies for Ulcerative Colitis in Tuscany: The MICHELANGELO Study 79
Lessons learnt from the preclinical discovery and development of ensitrelvir as a COVID-19 therapeutic option 77
COVID-19 Vaccines and Thromboembolic Events with Thrombocytopenia: Data from Italian Pharmacovigilance Public Database 73
Signals of Possibly Persistent Gustatory, Olfactory and Auditory Adverse Drug Reactions to Antibiotic Drugs: A Disproportionality Analysis Using the EudraVigilance Database 70
Preclinical discovery and development of the casirivimab + imdevimab cocktail for the treatment of novel coronavirus infection: the rise and fall 65
A Cross-National Comparison of Biosimilars Pricing in Argentina, Australia, Brazil, and Italy 64
Unresolved Gustatory, Olfactory and Auditory Adverse Drug Reactions to Antibiotic Drugs: A Signal Detection Analysis on Publicly Accessible Eudravigilance Data 59
Risk of Hospitalization Associated with Cardiovascular Medications in the Elderly Italian Population: A Nationwide Multicenter Study in Emergency Departments 57
Authors’ response: Inhibiting IL-6 in COVID-19: we are not sure that sgp130(fc) can affect only the trans-signaling receptor pathway of IL-6 52
Drug Safety and Relevant Issues in the Real-World 51
Real-world evidence and pharmacovigilance: workshop of the Italian Epidemiological Association and of the Italian Society of Pharmacology 27
Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors: A Scoping Review 17
Totale 10.844
Salva come PNG Salva come JPEG
Categoria #
all - tutte 37.055
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 37.055
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021159 0 0 0 0 0 0 0 0 0 0 0 159
2021/2022825 12 31 79 89 124 111 34 48 48 22 55 172
2022/20231.112 148 205 78 65 88 98 32 53 230 2 109 4
2023/2024927 34 53 64 32 102 149 100 60 39 46 119 129
2024/20253.046 43 116 114 216 222 380 232 101 306 354 321 641
2025/20264.043 348 243 345 329 396 201 544 146 281 336 811 63
Totale 10.844